Introduction
Supplementary Figure 1 . Eventually, 267 genetic mutations scattered across 19 loci were 159 included in our panel ( Table 1 and Supplementary Table 1) . 160 161 
214
Expert System, an in-house algorithm, was used to call nucleotide and amino-acid variants 215 from a pileup of aligned read bases. Low-quality variants were removed using a system of 216 adjustable filters, including (i) a noisy mutation filter, which removes variants called with a (ii) an allele frequency filtering, which excludes mutations with an allele frequency below a 219 defined threshold (10% by default) from the report.
220
The variants which passed the filters were then mapped using the mutation panel to identify 221 the presence of drug resistance mutations.
222
After the analysis, the software automatically generated two reports. The first, a one-page 223 clinical report, included the presence of drug resistance mutations with their allele 224 frequencies and drug resistance interpretations (Supplementary Fig.3) . The second, a full whereas the isolates from the Ethiopia were only subjected to MGIT 960 SIRE tests.
260
Unfortunately, pDSTs for LZD and BDQ were not performed in this study because of the 261 lack of a standardised pDST protocol and the unavailability of these drugs in the study 262 regions.
264
Diagnostic Performance Evaluation 265 The diagnostic sensitivities and specificities for each type of drug resistance in the 266 BacterioChek-TB reports based on MiSeq and MinION data were determined using standard 267 methods and compared to the gold-standard pDST results. The adjusted Wald method and 268 free online software (available from http://www.measuringusability.com/wald.htm) were 269 used to calculate the 95% confidence intervals (95% CI). The turnaround times of the sequencing methods were compared with that of pDST. proportionally with an increasing mutant/wild type ratio ( Fig.4) . For MiSeq, a drug-resistant 342 mutant DNA proportion of at least 20% was required to exceed the allele frequency threshold 343 of 10% for all six regions. For MinION, a drug-resistant subpopulation comprising at least 344 50% of the sample mixture was required to achieve an allele frequency of 40%. MinION sequencing platforms in a mixed population of wildtype and mutant at different ratios. The 348 mutant strain, WC-33, were found to harbour 6 multiple resistance-conferring mutations (katG 349
Ser315Thr, G > C genome position (P) 2155168; and XDR-TB isolates (n=10) in our collection.
377
Regarding the performance for prediction of resistance towards individual drugs, the 378 diagnostic sensitivities and specificities were presented in Table 3 . 
Discordance between pDST and Sequencing-Based Workflows
Discordant genotypic and phenotypic resistance data were observed for some isolates ( Table   5 ). Seven isolates which were phenotypically resistant to INH were inferred as susceptible by both sequencing workflows. Four of these isolates were found to harbour katG mutations outside our target panel and three of them did not have any variants identified in related targeted regions. Moreover, an isolate harboured a high-confidence mutation at codon 526 of rpoB was found to be phenotypically susceptible to RIF.
Sequencing-based workflows also failed to identify two (4.5%) PZA-resistant isolates. 
Turn-around Times and Cost Assessments of the MiSeq and MinION Sequencing

Workflows
The accumulated occupation hours from the DNA extraction from MGIT culture to the generation of a report by BacterioChek-TB were 38 and 15 hours for the MiSeq and MinION workflows, respectively. In a laboratory with daily working hours of 9:00 am to 5:00 pm, genotypic DSTs generated using the MiSeq and MinION workflows could be available in 4 and 3 days, respectively. In other words, the MiSeq and MinION workflows respectively reported drug susceptibility results for first-line agents 9 and 10 days earlier than the 13-day protocol required for MGIT 960 SIRE. A full-panel genotypic DST of 12 anti-TB agents could be delivered for treatment guidance at least 17 and 18 days earlier than the pDST results, respectively (Figure 5) .
The running costs per sample (including reagents and consumables) were US$67.83 for MiSeq sequencing (24 samples/run) and US$71.56 for MinION sequencing (12 samples/run) ( Table 6 ). Steps in the sequencing-based workflow However, we note that the numbers of samples in regional clinical centres that provide individualised care are unlikely to maximise the batching capacity of the MiSeq workflow.
Instead, smaller batch sizes might decrease the time-to-results by reducing the time needed to collect a minimum number of samples per batch. Therefore, the reduced capital cost, simpler workflow and lower-throughput capabilities favour the MinION over the MiSeq in regional clinical settings that provide individualised care. Conversely, MiSeq is a better choice in high-throughput settings such as reference laboratories, where sample batching can be optimised to minimise costs at the expense of workflow complexity and time.
This study had several shortcomings. First, cultures of archived M. tuberculosis strains were used as the input samples for sequencing. However, the ability to conduct sequencing on patient samples directly (i.e., without requiring a culture) will be more appropriate for both patient care and surveillance. Second, phenotypic drug resistance profiles were not equally available for all isolates included in this study, and test results were unavailable for BDQ and LZD. This variable availability of data limited the evaluation of our sequence-based assay, particularly for these two drugs. Finally, although we compiled several established drug resistance-associated mutations in our drug resistance mutation panel, not all these mutations were present in our collection of clinical isolates. Therefore, we could not assess the ability of our assays to detect these rare mutations.
Conclusions
Our study presented two targeted-sequencing workflows based on the 
